Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,095 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MCG Clear all
Completed Phase 4 Interventional Results available

A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease

NCT00257920
View directory record Official record
Conditions
Chronic Kidney Disease, Stage 5, Secondary Hyperparathyroidism
Interventions
Zemplar® injection, Hectorol® injection
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Bellevue, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 24, 2009 · Synced Oct 24, 2026, 10:40 PM EDT
Terminated Phase 4 Interventional Results available

A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging

NCT04435782
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
JNJ-67896049
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 64 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
La Jolla, California • Anderson, South Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 24, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

NCT03500679
View directory record Official record
Conditions
Healthy
Interventions
ExPEC4V, Placebo
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Wichita, Kansas • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 24, 2026, 10:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults

NCT06863142
View directory record Official record
Conditions
Influenza Prevention, Seasonal Influenza
Interventions
VRC-FLUMOS0116-00-VP, ALFQ
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 10:40 PM EDT
Withdrawn Phase 2 Interventional

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

NCT00528827
View directory record Official record
Conditions
Hypertension
Interventions
Cardene® I.V.
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Beverly Hills, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 24, 2026, 10:40 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

PROMMO Trial: Oral Misoprostol vs IV Oxytocin

NCT04478942
View directory record Official record
Conditions
Premature Rupture of Membrane, Induction of Labor Affected Fetus / Newborn
Interventions
Misoprostol Oral Product, Intravenous Oxytocin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 24, 2026, 10:40 PM EDT
Completed Phase 1 Interventional

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

NCT01170286
View directory record Official record
Conditions
Peanut Allergy
Interventions
Whole peanut extract, Placebo formulation
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 24, 2026, 10:40 PM EDT
Completed Phase 4 Interventional Results available

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

NCT02730351
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/ Vilanterol 100 mcg/25 mcg, Fluticasone propionate 250 mcg, Placebo via ELLIPTA inhaler, Placebo via DISKUS / ACCUHALER
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Huntington Beach, California • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 24, 2026, 10:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)

NCT00907153
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Vitamin D, Placebo
Dietary Supplement · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 24, 2026, 10:40 PM EDT
Terminated Phase 2 Interventional Results available

A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

NCT00726037
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Ontak
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 24, 2026, 10:40 PM EDT
Recruiting Phase 2 Interventional

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

NCT06529731
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Interferon gamma-1b, Donor Leukocyte Infusion (DLI)
Drug · Biological
Lead sponsor
Sawa Ito, MD
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 10:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

NCT00923351
View directory record Official record
Conditions
Neuroblastoma, Sarcoma, Rhabdomyosarcoma-Embryonal, Rhabdomyosarcoma- Alveolar, Neuroectodermal Tumors, Primitive, Peripheral
Interventions
Tumor Purged/CD25 Depleted Lymphocytes, Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine, rhIL-7, Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Months to 35 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 24, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

NCT02109172
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
TD-4208, Placebo
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 24, 2026, 10:40 PM EDT
Terminated Not applicable Interventional Results available

The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children

NCT00580151
View directory record Official record
Conditions
Pain, Anxiety
Interventions
clonidine, placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
4 Years to 20 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 24, 2026, 10:40 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Buccal Versus Vaginal Misoprostol In Combination With Foley Bulb

NCT03976037
View directory record Official record
Conditions
Induction of Labor
Interventions
Misoprostol
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 24, 2026, 10:40 PM EDT
Recruiting Phase 4 Interventional

Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine

NCT07316166
View directory record Official record
Conditions
Postoperative Pain Management
Interventions
Dexmedetomidine, Ropivacaine
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 24, 2026, 10:40 PM EDT
Completed Phase 4 Interventional

Effect of Chromium Picolinate on Insulin Sensitivity in Type 2 Diabetes

NCT00398853
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
chromium picolinate 1000 mcg daily vs placebo, Placebo
Dietary Supplement · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
25 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 24, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi Pasteur, TIV + H1N1, Pediatric Population

NCT00943202
View directory record Official record
Conditions
Influenza
Interventions
Inactivated H1N1 Vaccine, Trivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
531 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
8
States / cities
Atlanta, Georgia • Iowa City, Iowa • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 24, 2026, 10:40 PM EDT
Withdrawn Phase 2 Interventional

Dexmedetomidine Versus Chloral Hydrate for Pediatric Sedation During EEG

NCT00464451
View directory record Official record
Conditions
Procedural Sedation
Interventions
Dexmedetomidine, Chloral hydrate
Drug
Lead sponsor
Wesley Medical Center
Other
Eligibility
4 Months to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 24, 2026, 10:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery

NCT01138475
View directory record Official record
Conditions
Gastric Bypass, Parathyroid Hormone
Interventions
Paricalcitol, Cholecalciferol, Placebo
Drug
Lead sponsor
Kerstyn C. Zalesin, M.D.
Other
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 24, 2026, 10:40 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Vaccination With Tetanus and KLH to Assess Immune Responses.

NCT00000105
View directory record Official record
Conditions
Cancer
Interventions
Intracel KLH Vaccine, Biosyn KLH, Montanide ISA51, Tetanus toxoid
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 24, 2026, 10:40 PM EDT
Terminated Phase 2 Interventional

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

NCT00227656
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
PEG-interferon alfa-2a, Capecitabine
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Wichita, Kansas • Grand Rapids, Michigan • Springfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 24, 2026, 10:40 PM EDT
Completed Phase 2 Interventional

Oral Collagen for Rheumatoid Arthritis

NCT00000401
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Oral bovine type II collagen
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Jackson, Tennessee • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 24, 2026, 10:40 PM EDT
Completed Phase 2 Interventional

S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

NCT00023777
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
56 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
98
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 24, 2026, 10:40 PM EDT